智通财经APP获悉，派格生物医药-B(02565)尾盘涨超12%，截至发稿，涨12.59%，报63.5港元，成交额2820.11万港元。
消息面上，由派格生物自主研发的周制剂GLP-1RA维培那肽(派达康®)正式获中国国家药监局批准上市，用于治疗2型糖尿病(T2DM)。根据弗若斯特沙利文数据，2018年至2023年，全球T2DM药物市场规模复合年增长率约为29.3%。GLP-1受体激动剂的市场份额显著增长，从2018年的约8.4%增长至2023年的约29.3%。长效GLP-1受体激动剂因其更高的依从性，预计将在2032年占据中国GLP-1受体激动剂市场80%以上的份额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.